The goal of the Mayo Clinic Center for Cell Signaling in Gastroenterology (C-SiG) is to connect discovery, translational, and patient-oriented investigators to enhance understanding and therapeutically exploit signaling pathways in gastrointestinal cells to improve the health of patients with digestive diseases. The Research Base consists of 59 scientists and $23 million (direct costs, 70% growth) in digestive disease related funding. C-SiG members are organized into three Mechanistic Research Themes: 1) Ion channels/membrane receptors;ii) Signal transduction;and, iii) Genetics and gene regulation. Our CENTRAL HYPOTHESIS is that advances in clinical care of patients with digestive diseases requires a facilitative infrastructure supporting meaningful interactions among multidisciplinary scientists investigating cellular mechanisms, pathways and therapeutic targets to enhance rapid translation of basic discoveries into clinical trials. C-SiG's OVERALL SPECIFIC AIMS are to: i) Foster multidisciplinary research by expanding technical and collaborative capabilities of established Gl scientists and attracting investigators from other disciplines;li) Develop and implement a robust Scientific Enrichment Program that includes seminars, workshops, symposia, a visiting faculty program, minisabbatical, and Web-based curricula;iii) Offer specialized equipment, technologies, methodologies, reagents, and expertise to assist C-SiG members through the C-SiG Cores, including: a) State-of-the-art microscopic technology and consultative expertise (Optical Microscopy Core);b) Accelerated and expanded biospecimen acquisition, processing, and annotation (Clinical Core);c) Emerging genetic technologies and model systems (Genetics and Model Systems Core);iv) Identify and nurture new Gl investigators via a peer-reviewed Pilot and Feasibility Program;v) Promote synergistic interactions between C-SiG members and other Gl investigators at Mayo and at other Gl centers to facilitate clinical trials resulting from the identification of cellular therapeutic tarets;vi) Share technologies with other NIDDK centers at Mayo (e.g., PKD Center) and existing Digestive Disease Research Core Centers, especially in the Midwest (i.e. Midwest DDRCC Alliance).

Public Health Relevance

Gastrointestinal diseases and their complications have a significant effect on public health and health care utilization costs. Research supported by this Center grant, is critically important for furthering understanding of the mechanisms that underlie digestive diseases, which can lead to practical applications for the diagnosis, prevention, monitoring and treatment of human disease

National Institute of Health (NIH)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZDK1)
Program Officer
Grey, Michael J
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Yang, Liu; Kwon, Junghee; Popov, Yury et al. (2014) Vascular endothelial growth factor promotes fibrosis resolution and repair in mice. Gastroenterology 146:1339-50.e1
Guenzel, Adam J; Hillestad, Matthew L; Matern, Dietrich et al. (2014) Effects of adeno-associated virus serotype and tissue-specific expression on circulating biomarkers of propionic acidemia. Hum Gene Ther 25:837-43
Bi, Yan; Mukhopadhyay, Dhriti; Drinane, Mary et al. (2014) Endocytosis of collagen by hepatic stellate cells regulates extracellular matrix dynamics. Am J Physiol Cell Physiol 307:C622-33
White, Thomas A; LeBrasseur, Nathan K (2014) Myostatin and sarcopenia: opportunities and challenges - a mini-review. Gerontology 60:289-93
Peng, Ying; Clark, Karl J; Campbell, Jarryd M et al. (2014) Making designer mutants in model organisms. Development 141:4042-54
Yaqoob, Usman; Jagavelu, Kumaravelu; Shergill, Uday et al. (2014) FGF21 promotes endothelial cell angiogenesis through a dynamin-2 and Rab5 dependent pathway. PLoS One 9:e98130
Koh, Kwi Hye; Pan, Xian; Zhang, Wei et al. (2014) Kr├╝ppel-like factor 9 promotes hepatic cytochrome P450 2D6 expression during pregnancy in CYP2D6-humanized mice. Mol Pharmacol 86:727-35
Razumilava, Nataliya; Gradilone, Sergio A; Smoot, Rory L et al. (2014) Non-canonical Hedgehog signaling contributes to chemotaxis in cholangiocarcinoma. J Hepatol 60:599-605
Bhat, Mamatha; Chaiteerakij, Roongruedee; Harmsen, William S et al. (2014) Metformin does not improve survival in patients with hepatocellular carcinoma. World J Gastroenterol 20:15750-5
Tabibian, James H; O'Hara, Steven P; Splinter, Patrick L et al. (2014) Cholangiocyte senescence by way of N-ras activation is a characteristic of primary sclerosing cholangitis. Hepatology 59:2263-75

Showing the most recent 10 out of 156 publications